Foresight in clinical proteomics: current status, ethical considerations, and future perspectives
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 611 KB, PDF-dokument
With the advent of robust and high-throughput mass spectrometric technologies and bioinformatics tools to analyze large data sets, proteomics has penetrated broadly into basic and translational life sciences research. More than 95% of FDA-approved drugs currently target proteins, and most diagnostic tests are protein-based. The introduction of proteomics to the clinic, for instance to guide patient stratification and treatment, is already ongoing. Importantly, ethical challenges come with this success, which must also be adequately addressed by the proteomics and medical communities. Consortium members of the H2020 European Union-funded proteomics initiative: European Proteomics Infrastructure Consortium-providing access (EPIC-XS) met at the Core Technologies for Life Sciences (CTLS) conference to discuss the emerging role and implementation of proteomics in the clinic. The discussion, involving leaders in the field, focused on the current status, related challenges, and future efforts required to make proteomics a more mainstream technology for translational and clinical research. Here we report on that discussion and provide an expert update concerning the feasibility of clinical proteomics, the ethical implications of generating and analyzing large-scale proteomics clinical data, and recommendations to ensure both ethical and effective implementation in real-world applications.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 59 |
| Tidsskrift | Open Research Europe |
| Vol/bind | 3 |
| Antal sider | 19 |
| ISSN | 2732-5121 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
This manuscript is part of the efforts of European Proteomics Infrastructure Consortium - Providing Access (EPIC-XS), which is a project funded by the European Union to provide proteomics expertise and mass spectrometry technology to researchers within the life science arena ( https://epic-xs.eu/ ). It brings together eighteen institutes, spread across fifteen European countries, with the objective of providing more than 2,400 days of access to high-end proteomics technologies. The EPIC-XS consortium tackles fundamental aspects of the consolidation and enhancement of proteomics technologies and skills across Europe. The EPIC-XS infrastructure contributes to strengthening Europe’s leading role in proteomics by ensuring access of a broad range of researchers to prominent European proteomics facilities, on the premise that research in this field can yield information spanning the whole life science domain, including developments towards potential disease biomarkers. EPIC-XS has an independently appointed ethics advisor to help the consortium ensure the compliance of the project with ethical standards (national and EU) and guidelines of the H2020 program.
Funding Information:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823839 (European Proteomics Infrastructure Consortium providing Access [EPIC-XS]). Nicolai J. Wewer Albrechtsen is supported by an NNF Excellence Emerging Investigator Grant – Endocrinology and Metabolism (Application No. NNF19OC0055001), EFSD Future Leader Award (NNF21SA0072746), and DFF Sapere Aude (1052-00003B). Novo Nordisk Foundation Center for Protein Research is supported financially by the Novo Nordisk Foundation (Grant agreement NNF14CC0001). The Netherlands Proteomics Centre (AJRH) acknowledges support from the Netherlands Organization for Scientific Research (NWO) through the X-omics Road Map program (project 184.034.019). JAV wants to acknowledge funding from Wellcome (223745/Z/21/Z) and EMBL core funding.
Publisher Copyright:
Copyright: © 2023 Mundt F et al.
ID: 366766830